Casein kinase 2 antisense therapy
AssigneeRegents of the University of Minnesota
InventorsJoel W. Slaton, Khalil Ahmed, Gretchen M. Unger, Alan Davis, Dan Sloper
Life of this patent
Estimating the term…
Abstract
The invention provides for antisense oligonucleotides that hybridize to casein kinase 2 nucleic acid sequences and methods of using such antisense oligonucleotides to inhibit expression of casein kinase 2 and reduce the size of solid tumors.
Claims21
A method of inhibiting the expression of casein kinase 2 in a solid tumor, comprising:
- delivering an antisense oligonucleotide to said tumor, wherein said antisense oligonucleotide has the sequence shown in SEQ ID NO:7.
A method of reducing the size of a solid tumor in an individual, comprising
- delivering an antisense oligonucleotide to said tumor, wherein said antisense oligonucleotide hybridizes to casein kinase 2 nucleic acid sequences and reduces the expression thereof, wherein said antisense oligonucleotide has the sequence shown in SEQ ID NO:7,
- wherein said reduction in expression of casein kinase 2 results in a reduction in size of said tumor.
A composition comprising an antisense oligonucleotide and a pharmaceutically acceptable carrier, wherein said antisense oligonucleotide hybridizes to casein kinase 2 nucleic acid sequences and reduces the expression thereof, wherein said antisense oligonucleotide has the sequence shown in SEQ ID NO:7.
An antisense oligonucleotide of up to 50 nucleotides in length comprising a portion of at least 8 consecutive nucleotides of SEQ ID NO:7 , wherein said antisense oligonucleotide inhibits the expression of human casein kinase 2α.
An antisense oligonucleotide of up to 50 nucleotides in length comprising a portion of at least 8 consecutive nucleotides of SEQ ID NO:7, wherein said antisense oligonucleotide inhibits the expression of human casein kinase 2α and 2α′.
Dependencies are inferred from the claim text.